Equities Analysts Offer Predictions for REVB FY2024 Earnings

Revelation Biosciences, Inc. (NASDAQ:REVB) – Investment analysts at Zacks Small Cap lifted their FY2024 earnings per share estimates for Revelation Biosciences in a research note issued to investors on Monday, November 11th. Zacks Small Cap analyst B. Sorensen now anticipates that the company will earn ($9.38) per share for the year, up from their previous forecast of ($16.32). The consensus estimate for Revelation Biosciences’ current full-year earnings is ($7.80) per share. Zacks Small Cap also issued estimates for Revelation Biosciences’ Q4 2024 earnings at ($0.95) EPS, Q1 2025 earnings at ($0.85) EPS, Q2 2025 earnings at ($0.82) EPS, Q3 2025 earnings at ($0.80) EPS, Q4 2025 earnings at ($0.78) EPS and FY2025 earnings at ($3.25) EPS.

Revelation Biosciences Stock Performance

Shares of REVB opened at $0.91 on Wednesday. Revelation Biosciences has a fifty-two week low of $0.70 and a fifty-two week high of $25.26. The firm has a market cap of $1.49 million, a price-to-earnings ratio of -0.05 and a beta of 0.15. The firm has a 50 day moving average price of $0.85 and a 200-day moving average price of $1.43.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.